US-based multinational pharmaceutical giant Eli Lilly & Co., on Tuesday, 17 June 2025, announced its plans to acquire gene-editing biotech firm Verve Therapeutics Inc. for $1.3 billion as the big pharma company eyes expansion in experimental medicine…
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here’s why
